> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Voucher Awarded to Genzyme
- URL: https://www.fdaweb.com/priority-voucher-awarded-to-genzyme/
- Published: 2023-12-04T12:00:00.000Z
- Updated: 2026-09-14T14:17:39.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5155912

*Federal Register* notice: FDA is announcing that it has issued a priority review voucher to Genzyme after gaining a qualified approval for Xenpozyme (olipudase alfa-rpcp), indicated for treating non-central nervous system manifestations of acid sphingomyelinase deficiency. The voucher was awarded under the agency’s voucher program for rare pediatric disease products. To view the notice, click [here](https://public-inspection.federalregister.gov/2023-26652.pdf?ref=fdaweb.com).